Quest PharmaTech, Inc.

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its October 8, 2024 annual general meeting of shareholders. The Company announces the following four directors have been elected to the Company’s Board of Directors: J. Mark Lievonen, C.M., FCPA, FCA, LLD Jeffrey Shon, J. DBradley J. Glass J.DMadi R. Madiyalakan, Ph.D. At the meeting, shareholders reappointed the Company’s auditors, Kingston Ross Pasnak, LLP. “I would like to thank all of our Board members for their service to the Company,” said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest. “I am confident that Quest’s Board of Directors will be able to help the Company execute its business strategy to add value to our shareholders.” Approximately 75,392,253 shares were voted for the Company’s shareholder meeting representing approximately 44.58% of the Company’s shares eligible to vote. On a corporate matter, Quest announces the granting of 1,800,000 stock options to Directors and Officers, all at a volume weighted average exercise price of $0.05 per common share, expiring 10 years from the date of grant, subject to TSX Venture Exchange approval. About Quest PharmaTech Inc. Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing the proprietary MAb-AR9.6 targeting MUC16 as theranostic agents for cancer. MAb-AR9.6 was licensed from the University of Nebraska Medical Centre and currently is in late preclinical stage development. The Company also has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. To learn more, visit www.questpharmatech.com. Forward Looking Statements Statements on the development and potential of the Company’s MAb AR9.6 product candidate constitute forward-looking statements. Such statements are based on the current expectations of management and inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Quest’s control. These risks include the achievement of forecasted development milestones, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed and other risks disclosed in the Company’s Management’s Discussion & Analysis and other public fillings at www.sedarplus.ca. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Quest is under no obligation and has no intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable law. For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc.Tel: (780) 448-1400, Email: madi@questpharmatech.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- The surge in colposcopy device demand is mainly driven by a growing incidence of cervical disorders like cervical cancer and inflammatory alterations in the vulva, vagina, and cervix. Additionally, factors such as heightened awareness of early diagnosis, a growing embrace of advanced technologies, continuous product introductions and approvals, among others, collectively contribute to the overall expansion of the colposcopy devices market anticipated between 2023 and 2028. DelveInsight's Colposcopy Devices Market Insights report provides the current and forecast market analysis, individual leading colposcopy devices companies' market shares, challenges, colposcopy devices market drivers, barriers, trends, and key market colposcopy devices companies in the market. Key Takeaways from the Colposcopy Devices Market Report As per DelveInsight estimates, North America is anticipated to dominate the global colposcopy devices market during the forecast period. Notable colposcopy devices companies such as McKesson Medical-Surgical Inc., ZEISS, Olympus America, MEDGYN PRODUCTS, INC., Liger Medical, LLC., DYSIS Medical Inc, ATMOS MedizinTechnik GmbH & Co. KG, Ecleris, Optomic, Seiler Instrument Inc., Karl Kaps GmbH & Co. KG, Narang Medical Limited., SCHMITZ, Lutech, Centrel, Hunan Fude Technology Co., Ltd., Kernel Medical Equipment Co., Ltd., Delmont imaging, Biomedicinos, SCANER Science & Engineering center, and several others, are currently operating in the colposcopy devices market. In August 2021, DYSIS Medical Inc. launched DYSIS View, a compact and portable colposcope, which includes the company's innovative computer-aided cervical mapping technology that helps healthcare professionals detect cervical lesions more clearly. In April 2021, Liger Medical, LLC received FDA approval for IRIS Thermocoagulator and Digital Colposcope device. The device is intended for the destruction of human tissue with high temperatures by tissue contact with an electrically heated probe, and to provide magnified visualization of the tissues of the vagina, cervix, and external genitalia to aid in selecting areas for biopsy and diagnosing abnormalities as needed for a colposcopy exam. To read more about the latest highlights related to the colposcopy devices market, get a snapshot of the key highlights entailed in the Global Colposcopy Devices Market Report Colposcopy Devices Overview Colposcopy devices play a crucial role in the field of gynecology and women's health by providing a detailed and magnified examination of the cervix, vagina, and vulva. These specialized instruments are employed to investigate and diagnose abnormalities, such as cervical dysplasia or cancerous lesions, that may not be easily visible to the naked eye. During a colposcopic examination, a colposcope—an illuminated, binocular microscope—is used to magnify the cervical tissues, allowing healthcare professionals to detect any irregularities and take targeted biopsies if necessary. Additionally, colposcopy devices often incorporate advanced features, such as digital imaging and video capabilities, enhancing documentation and communication among healthcare providers. This non-invasive and highly effective diagnostic technique serves as a vital tool in the early detection and management of various gynecological conditions, ultimately contributing to improved outcomes for women's health. Colposcopy Devices Market Insights In 2022, North America dominated the colposcopy devices market, primarily due to the increasing incidence of cervical cancer and other factors. The region benefits from a robust healthcare infrastructure, a surge in product launches and approvals, and growing regulatory support for new healthcare products. As the prevalence of cervical cancer rises, there is a heightened demand for colposcopes, driving colposcopy devices market growth. The need for colposcopes is expected to escalate as more individuals undergo cervical cancer screening, necessitating investments by healthcare institutions to ensure swift and accurate diagnoses. The North American government has implemented initiatives to address cervical cancer, expanding insurance coverage for cervical screening examinations, particularly for low-income women. Efforts are also underway to integrate HPV vaccines into federal programs, further contributing to insurance coverage. These collective factors create a conducive environment for the growth of the colposcopy devices market in North America. To know more about why North America is leading the market growth in the colposcopy devices market, get a snapshot of the Colposcopy Devices Market Outlook Colposcopy Devices Market Dynamics The colposcopy devices market is experiencing a positive surge in product demand due to several factors, with a notable factor being the rise in cervical cancer cases. Additionally, there is an increasing demand for advanced colposcopy instruments to support treatments as healthcare professionals and patients become more aware of the benefits of minimally invasive procedures. These instruments often incorporate cutting-edge technology such as advanced optics and high-resolution imaging systems, enhancing visualization and accuracy during colposcopy examinations. The necessity for such devices is motivated by the goal of improving diagnostic precision, ensuring patient comfort, and enabling early detection of cervical anomalies. Consequently, the growing awareness of minimally invasive diagnostics is expected to drive the demand for colposcopy devices in the forecast period. Furthermore, the colposcopy devices market is likely to be influenced by increasing research and developmental activities, product launches, approvals, and other strategic initiatives. Nevertheless, challenges such as patient discomfort and anxiety during colposcopy examinations, the high costs associated with colposcopy devices and procedures, and other factors may impede the growth of the colposcopy devices market. Get a sneak peek at the colposcopy devices market dynamics @ Colposcopy Devices Market Dynamics Analysis Colposcopy Devices Market Assessment Colposcopy Devices Market Segmentation Colposcopy Devices Market Segmentation By Product: Optical and Digital Colposcopy Devices Market Segmentation By Portability: Stationary and Handheld Colposcopy Devices Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and Others Colposcopy Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the colposcopy devices market are set to emerge as the trendsetter explore @ Colposcopy Devices Companies Table of Contents Interested in knowing the colposcopy devices market by 2028? Click to get a snapshot of the Colposcopy Devices Market Trends Related Reports Womens Health Market Womens Health Market Insights, Epidemiology, and Market Forecast – 2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key women's health companies including AbbVie Inc., Abbott, Eli Lilly and Company, Agile Therapeutics®, Willow Innovations, Inc., Pfizer Inc., LUPIN, AstraZeneca, Torrent Pharmaceuticals Ltd., Bayer AG, Renovia Inc., Hologic, Inc, BD, Koninklijke Philips N.V., Danaher, The Feminina Group Inc., Chiaro Technology Ltd., Redcliffe Hygiene Private Limited, AceWin Co., Ltd., Pigeon Corporation, among others. FemTech Market FemTech Market Insights, Epidemiology, and Market Forecast – 2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key FemTech companies including HeraMED, Sera Prognostics, iSono Health, Inc., Flo Health Inc., NUVO Inc., Natural Cycles USA Corp, Athena Feminine Technologies, Inc., NUROKOR LIMITED, Canopie, Univfy Inc., Glow Inc., Clue by Biowink GmbH, Oura Health Oy., Ava, Laboratory Corporation of America® Holdings, Baymatob Operations Pty. Ltd., Expectful, Evofem Biosciences, Inc., March Inc., Syantra Inc., among others. Ovarian Cancer Pipeline Ovarian Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including IMV, Elucida Oncology, Chia Tai Tianqing Pharmaceutical Group, Precigen, Inc, Glycotope GmbH, Sonnet Biotherapeutics, Allarity Therapeutics, Adimab, Mersana Therapeutics, Genentech, Genmab, Merck, OncoQuest, IMPACT Therapeutics, among others. Cervical Cancer Pipeline Cervical Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cervical cancer companies, including Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene, MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories, Jiangsu Chia Tai Tianqing Pharmaceutical, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus, Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Genentech, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +91-9650213330 SOURCE DelveInsight Business Research, LLP

Quest PharmaTech announced that a pivotal study of CanariaBio’s oregovomab in front-line ovarian cancer failed to hit its ​​progression-free survival (PFS) goal at an interim futility analysis. The Phase III FLORA-5 trial is investigating oregovomab with a standard six-cycle chemotherapy regimen in 615 newly diagnosed patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma, focusing on both adjuvant and neoadjuvant cohorts. Along with the primary endpoint of PFS in the two cohorts, secondary goals include overall survival (OS).Hopes pinned on OSQuest noted that while the data safety monitoring board recommended that the study be halted, follow-up should continue as “there is a possibility of significant efficacy” in OS. The company added that it is in talks with the trial’s sponsor, CanariaBio, around continued support of the clinical programme for the CA-125-directed monoclonal antibody.CanariaBio gained oregovomab after OncoQuest, in which Quest holds a 42.5% stake, sold rights to another Korean-based company.The decision to stop the study is likely to put a dampener on CanariaBio’s global plans for oregovomab, including a string of recent licensing deals to market the drug in Australia, New Zealand, and select Southeast Asian countries with Specialised Therapeutics, and in the Middle East and North Africa region with Hikma Pharmaceuticals.